Contact David

Speaking Engagements

  

Oligonucleotide Therapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material utilising oligonucleotide conjugates, antisense oligonucleotides (ASOs), mRNA and RNAi.

21-22 September 2022
  

Bringing together both technical and strategic expertise sharing case studies with actionable insights, the 4th RNAi-Based Therapeutics Summit returns to Boston to address the most pressing challenges preventing the widespread adoption of RNAi therapies and tackling targets beyond the liver.

21-23 March 2023